2024
PD-1H/VISTA Agonism Inhibits Host Myeloid Antigen Presenting Cells That Suppresses Acute Graft-Versus-Host Disease without Losing Graft-Versus-Leukemia Effect
Hu Q, Fielder C, Huh W, Kassim A, Kim T. PD-1H/VISTA Agonism Inhibits Host Myeloid Antigen Presenting Cells That Suppresses Acute Graft-Versus-Host Disease without Losing Graft-Versus-Leukemia Effect. Transplantation And Cellular Therapy 2024, 30: s253. DOI: 10.1016/j.jtct.2023.12.336.Peer-Reviewed Original ResearchMyeloid antigen-presenting cellsHost antigen-presenting cellsAntigen-presenting cellsBone marrow transplantationMyeloid-derived suppressor cellsAllogeneic T cell proliferationAcute GVHDAcute GVHD symptomsGraft-versus-leukemiaPD-1HT cell proliferationHost miceT cellsBMT modelIsotype controlGraft-versus-leukemia (GVLSuppress acute graft-versus-host diseaseMHC-mismatched bone marrow transplantationAcute graft-versus-host diseaseT cell priming phaseGraft-versus-host diseaseMismatched bone marrow transplantationMyeloid antigen presenting cellsAcute GVHD treatmentDonor T cells
2023
Mucosal immune alterations at the early onset of tissue destruction in chronic obstructive pulmonary disease
de Fays C, Geudens V, Gyselinck I, Kerckhof P, Vermaut A, Goos T, Vermant M, Beeckmans H, Kaes J, Van Slambrouck J, Mohamady Y, Willems L, Aversa L, Cortesi E, Hooft C, Aerts G, Aelbrecht C, Everaerts S, McDonough J, De Sadeleer L, Gohy S, Ambroise J, Janssens W, Ceulemans L, Van Raemdonck D, Vos R, Hackett T, Hogg J, Kaminski N, Gayan-Ramirez G, Pilette C, Vanaudenaerde B. Mucosal immune alterations at the early onset of tissue destruction in chronic obstructive pulmonary disease. Frontiers In Immunology 2023, 14: 1275845. PMID: 37915582, PMCID: PMC10616299, DOI: 10.3389/fimmu.2023.1275845.Peer-Reviewed Original ResearchConceptsCD8+ T cell accumulationT cell accumulationImmune alterationsTerminal bronchiolesTissue destructionCOPD lungsCD4+ T cellsMyeloid antigen-presenting cellsAntigen-presenting cellsSmall airway changesTissue destructive processesChronic airway inflammationInnate immune alterationsB cell activationMucosal immune defenseAdaptive immune responsesChronic obstructive pulmonary diseaseObstructive pulmonary diseaseIncreased mucus productionAlveolar surface densityAirway changesT cellsAirway inflammationImmune cellsB cells
2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.Peer-Reviewed Original ResearchConceptsPD-L1 blockadePD-1 blockadeAsymptomatic multiple myelomaMonocyte-derived DCsPD-L1Immunologic effectsT cellsMyeloid cellsAntigen-specific T cell expansionAnti-PD-1 therapyMyeloid antigen-presenting cellsDistinct inflammatory signatureSystemic immunologic effectsLung cancer patientsT cell expansionAntigen-presenting cellsMyeloid activationMyeloid inflammationInflammatory signatureNIH/NCICheckpoint blockadeDC maturationL1 therapyCombination therapyInflammatory phenotype
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply